The Food and Drug Administration approved Hibsago (bepirovirsen) on Oct. 20, 2026, calling it the first-of-its-kind treatment for chronic hepatitis B and the first antisense oligonucleotide cleared for the infection. The drug is an injection given under the skin for up to 24 weeks, and it is designed to be added to the antiviral medicine that patients already take.
Tech news worth reading: Get Techpresso, the daily email with the most interesting tech news and insights, read by 400,000+ professionals from Google, Apple and OpenAI.
We may earn a commission if you sign up.
In the trials the agency reviewed, 24% of patients who received Hibsago met the requirements to stop their existing hepatitis B medicine, compared with none of the patients given a placebo. The approval is for a defined group of adults, and the label carries a boxed warning about the liver. For people who have taken daily antiviral pills for years, the prospect of stepping off them is the draw, but the numbers show that most patients will not get there, and the agency built the label around that reality.
Who can receive the Hibsago injection
The FDA announcement limits the approval to certain adults without cirrhosis. Candidates must have taken hepatitis B antiviral therapy for at least six months, have suppressed virus levels in the blood, and have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less, as determined by an FDA-authorized test. The agency also authorized the Roche Elecsys HBsAg II quant II RxDx assay to help select patients and to monitor them during treatment.
Chronic hepatitis B is a long-term liver infection caused by the hepatitis B virus. Over time it can lead to serious liver disease, including cirrhosis, and it raises the risk of liver cancer. Patients in the approved group are already on antiviral therapy with their virus suppressed, which is why a finite course of injections that lets some stop therapy is treated as a meaningful change in approach. The FDA’s announcement does not include prevalence figures, so this article does not estimate how many people could be eligible.
How an antisense drug targets the virus
Hibsago is an antisense oligonucleotide, a short strand of genetic material that targets the instructions the virus uses to make copies of itself and to produce viral proteins. By interfering with that step, the drug reduces both virus and HBsAg levels. Wendy Carter, acting director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said “Hibsago provides a new treatment approach” and called the approval “an important advance for people living with this serious disease.”
The regimen differs from current care in its structure. Patients take Hibsago alongside their existing hepatitis B medicine and must continue that medicine for at least 24 weeks after the last injection. Only then may some patients stop it, and only if they meet certain health and laboratory requirements. That long tail of continued antiviral treatment is part of the design: the injection is an add-on during a defined window, and the decision to stop is made afterward on the basis of laboratory results, not on the calendar alone.
What two placebo-controlled trials showed
The agency says two clinical trials compared Hibsago with a placebo. Twenty-four percent of Hibsago patients met the requirements to stop their existing medicine, and none of the placebo patients did. Another measure tracked who held up after treatment ended: 24 weeks after stopping all hepatitis B treatment, 19% of Hibsago patients still had the virus under control, with HBsAg undetectable in the blood. Read side by side, 24% and 19% show how many patients cleared the first bar and how many held the result after treatment ended.
The result is a partial one. Most patients in the trials did not reach the point of stopping their medicine, so the drug is best understood as a way for a minority to step off long-term therapy, not as a replacement for it. GSK, which makes the drug, has also won clearance in Japan, according to EMJ Reviews, which reported that late-stage trials showed about one in five patients reaching a functional cure.
Boxed warning, side effects and fast-track status
Hibsago carries a boxed warning for serious liver reactions and low platelet counts, which can raise the risk of potentially life-threatening bleeding. The label also warns of worsening kidney function, serious inflammatory reactions such as vasculitis, and serious risks if the injection is not given correctly. Patients need regular blood tests and follow-up with a health care provider before and during treatment. The most common side effects, leaving aside lab abnormalities, were injection site reactions, fever, fatigue and headache.
The product received three expedited designations before approval: Fast Track, Breakthrough Therapy and Priority Review. Those programs exist to speed development and review of treatments for serious conditions, and the agency applied all three to this product. For patients and clinicians the practical questions now are who meets the surface antigen cutoff, who has no cirrhosis, and who is willing to commit to the monitoring schedule that the boxed warning implies. The same two-test logic applies on the way in and on the way through treatment, since the companion assay is used both to pick patients and to follow them. Anyone who has a problem with a drug can report it through the FDA’s product problem reporting page.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
Tech news worth reading: Get Techpresso →
We may earn a commission if you sign up.
More from Morning Overview
- Long use of a common prostate pill is tied to a higher chance of glaucoma
- Ford is recalling 223,472 F-150 pickups because the fuel tank can leak or detach
- Hybrids have 15% fewer problems than gas cars, while EVs and plug-in hybrids have about 80% more, Consumer Reports finds
- Regulators cleared the first U.S. small modular reactor, 4 months early
